These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 34822842)
21. Overexpression of deubiquitinating enzyme USP28 promoted non-small cell lung cancer growth. Zhang L; Xu B; Qiang Y; Huang H; Wang C; Li D; Qian J J Cell Mol Med; 2015 Apr; 19(4):799-805. PubMed ID: 25656529 [TBL] [Abstract][Full Text] [Related]
22. UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5. Li J; Liang Y; Zhou S; Chen J; Wu C Breast Cancer Res; 2024 Mar; 26(1):44. PubMed ID: 38468288 [TBL] [Abstract][Full Text] [Related]
23. Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer. Sheng J; Xue X; Jiang K Curr Mol Med; 2019; 19(2):147-155. PubMed ID: 30854965 [TBL] [Abstract][Full Text] [Related]
24. The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer. Wu X; Zahari MS; Renuse S; Kelkar DS; Barbhuiya MA; Rojas PL; Stearns V; Gabrielson E; Malla P; Sukumar S; Mahajan NP; Pandey A Oncotarget; 2017 Jan; 8(2):2971-2983. PubMed ID: 27902967 [TBL] [Abstract][Full Text] [Related]
25. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer. Thies KA; Cole MW; Schafer RE; Spehar JM; Richardson DS; Steck SA; Das M; Lian AW; Ray A; Shakya R; Knoblaugh SE; Timmers CD; Ostrowski MC; Chakravarti A; Sizemore GM; Sizemore ST Breast Cancer Res; 2021 Jun; 23(1):65. PubMed ID: 34118960 [TBL] [Abstract][Full Text] [Related]
26. The deubiquitinating enzyme STAMBP is a newly discovered driver of triple-negative breast cancer progression that maintains RAI14 protein stability. Yang Q; Yan D; Zou C; Xue Q; Lin S; Huang Q; Li X; Tang D; Chen X; Liu J Exp Mol Med; 2022 Nov; 54(11):2047-2059. PubMed ID: 36434041 [TBL] [Abstract][Full Text] [Related]
27. miR-221/222 activate the Wnt/β-catenin signaling to promote triple-negative breast cancer. Liu S; Wang Z; Liu Z; Shi S; Zhang Z; Zhang J; Lin H J Mol Cell Biol; 2018 Aug; 10(4):302-315. PubMed ID: 30053090 [TBL] [Abstract][Full Text] [Related]
28. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer. Li M; Li A; Zhou S; Lv H; Yang W J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840 [TBL] [Abstract][Full Text] [Related]
29. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267 [TBL] [Abstract][Full Text] [Related]
30. The deubiquitinase USP28 controls intestinal homeostasis and promotes colorectal cancer. Diefenbacher ME; Popov N; Blake SM; Schülein-Völk C; Nye E; Spencer-Dene B; Jaenicke LA; Eilers M; Behrens A J Clin Invest; 2014 Aug; 124(8):3407-18. PubMed ID: 24960159 [TBL] [Abstract][Full Text] [Related]
31. Altered RECQL5 expression in urothelial bladder carcinoma increases cellular proliferation and makes RECQL5 helicase activity a novel target for chemotherapy. Patterson K; Arya L; Bottomley S; Morgan S; Cox A; Catto J; Bryant HE Oncotarget; 2016 Nov; 7(46):76140-76150. PubMed ID: 27764811 [TBL] [Abstract][Full Text] [Related]
32. USP28 regulates deubiquitination of histone H2A and cell proliferation. Li F; Han H; Sun Q; Liu K; Lin N; Xu C; Zhao Z; Zhao W Exp Cell Res; 2019 Jun; 379(1):11-18. PubMed ID: 30910399 [TBL] [Abstract][Full Text] [Related]
33. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer. Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378 [TBL] [Abstract][Full Text] [Related]
34. Targeting RECQL5 Functions, by a Small Molecule, Selectively Kills Breast Cancer Chakraborty S; Dutta K; Gupta P; Das A; Das A; Ghosh SK; Patro BS J Med Chem; 2021 Feb; 64(3):1524-1544. PubMed ID: 33529023 [TBL] [Abstract][Full Text] [Related]
35. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer. Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514 [TBL] [Abstract][Full Text] [Related]
36. USP28 promotes aerobic glycolysis of colorectal cancer by increasing stability of FOXC1. Liu Z; Chen M; Xu X; Zhang L; Pan Y; Chen D Acta Biochim Pol; 2021 Jun; 68(4):633-639. PubMed ID: 34106567 [TBL] [Abstract][Full Text] [Related]
37. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer. Brand TM; Iida M; Dunn EF; Luthar N; Kostopoulos KT; Corrigan KL; Wleklinski MJ; Yang D; Wisinski KB; Salgia R; Wheeler DL Mol Cancer Ther; 2014 May; 13(5):1356-68. PubMed ID: 24634415 [TBL] [Abstract][Full Text] [Related]
38. PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis. Paul A; Gunewardena S; Stecklein SR; Saha B; Parelkar N; Danley M; Rajendran G; Home P; Ray S; Jokar I; Vielhauer GA; Jensen RA; Tawfik O; Paul S Cell Death Differ; 2014 Sep; 21(9):1469-81. PubMed ID: 24786829 [TBL] [Abstract][Full Text] [Related]
39. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer. Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349 [TBL] [Abstract][Full Text] [Related]
40. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer. Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]